Clinical Trial Detail

NCT ID NCT03471351
Title Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors Rhizen Pharmaceuticals SA
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab + RP6530

Age Groups: adult senior

No variant requirements are available.